HK Stock Market Move | HBM Holdings-B (02142) surges by over 8%, the company has repurchased shares for five consecutive days, with a total repurchase of over 70 million Hong Kong dollars so far this year.

HBM HOLDINGS-B (02142) rose by more than 8%, reaching 7.32% at the time of publication, at 8.8 Hong Kong dollars, with a turnover of 60.909 million Hong Kong dollars. On the news front, Hebo Pharmaceuticals announced on May 12th that the company spent 9.76 million Hong Kong dollars to repurchase 1.2 million shares. According to WIND data, in just five months since the beginning of 2025, the company has spent 70.188 million Hong Kong dollars to repurchase 14.078 million shares. In May alone, the company has continued repurchasing for five consecutive days, with a total repurchase amount of 29.686 million Hong Kong dollars. It is reported that in March, Hebo Pharmaceuticals signed a global strategic cooperation agreement with AstraZeneca to jointly develop a new generation of multispecific antibodies for immunological diseases, tumors, and other diseases. Pacific Securities pointed out that Hebo Pharmaceuticals has received AstraZeneca's favor multiple times. In addition to AstraZeneca, Hebo Pharmaceuticals has also reached cooperation agreements with many other MNCs such as Pfizer and AbbVie. The favor of MNCs towards Hebo Pharmaceuticals is based on its proprietary HarbourMice fully human antibody technology platform and NoNa biotechnology platform.